UW-Madison announced on Wednesday it was one of 32 sites for a clinical trial testing an existing drug called ruxolitinib as a way to prevent a COVID-19 complication where a patient’s immune system kicks into deadly overdrive. Hospitals in Milwaukee and Madison are also investigating convalescent plasma from recovered patients to treat those with active infections.
Office of Strategic Communication